



Fact Sheet

Q1 2016


Issued May 2016 | ir.tevapharm.com

CONTACT INFORMATION: Kevin Mannix | Tel: +1 (215) 591-8912 Email: kevin.mannix@tevapharm.com Ran Meir | Tel: +1 (215) 519 - 3033 Email: Ran.Meir@tevapharm.com


Company Overview

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to \$19.7 billion. For more information, visit www.tevapharm.com.

Continued Improvement in Earnings and Cash Flow




12 Month Stock Performance (as of May 11)




Net Revenues

(USD m)




Operating Income (non GAAP¹)

(USD m)




Earnings Per Share (non GAAP¹)

(USD)



Dividends Per Share

(USD)



(1) See non GAAP reconciliation in our report for the (1th Quarter 2016)

Defend

- Deliver our operational and financial targets for 2016
- Defend Copaxone® and Bendeka™

Integrate & Extract Synergies



- Actavis Generics deal closing and integration
- Capturing all planned synergies
 - Rimsa
 - Teva-Takeda BV in Japan

Build

- FDA Approvals:
 - SD-809 in HD
 - Vantrela® ER HC
- Key clinical milestones:
 - Submission: QVAR® BAI for asthma
 - PIII: SD-809 in tardive dyskinesia
 - PIII: TV-46763 for pain
 - PII: Pridopidine for HD


Revenues by Markets and Segments

Q1 - 2016



Profit** by Segment

Q1 - 2016



* Other activities include our OTC business with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices

** Profit consists of gross profit, less S&M and R&D expenses related to the segment. Segment profitability does not include G&A expenses, amortization and certain other items.

Teva Specialty pipeline

Phase 1	Phase 2	Phase 3	Registration
TV-46139 (abuse deterrent) Pain	TV-45070 Topical Neuropathic pain	TEV-48125 (anti CGRP) Chronic and episodic migraine	Vantrela ER abuse deterrent Hydrocodone US Pain
TEV-90105 (abuse deterrent) Pain	Laquinimod Multiple sclerosis (progressive forms)	TV-46763 (abuse deterrent) Pain	TEV-90109 Opioid addiction
SD-809 (deutetrabenazine) Tourette syndrome	Laquinimod Huntington disease	Laquinimod Multiple sclerosis (relapsing remitting)	Copaxone® 40mg 3w ROW Multiple sclerosis
SD-1077 (deuldopa) Parkinson's Disease	Pridopidine Huntington disease	SD-809 (deutetrabenazine) Tardive dyskinesia	SD-809 (deutetrabenazine) Huntington Disease
Fluticasone Salmeterol (MDI) EU Asthma, COPD	CEP-41750 (mesenchymal precursor cell) Acute myocardial infarction	QVAR® (BAI) US Asthma	Reslizumab IV Global Asthma – APPROVED in US*
SD-560 (deupirfenidone) Idiopathic pulmonary fibrosis		Reslizumab SC Global Asthma	TV-44663 Fluticasone Propionate RespiClick® US Asthma
TEV-46017 (tidal inhaler) COPD		CEP-41750 (mesenchymal precursor cell) Chronic heart failure	TV-44664 Fluticasone Salmeterol RespiClick® US Asthma
TEV-48107 (tidal inhaler) COPD			Fluticasone Salmeterol Spiromax EU Asthma, COPD
TEV-90110, TEV-90111, TEV-90112, TEV-90113 HIV			

- Migraine & Pain
- Movement Disorders & Neurodegeneration
- Respiratory
- Other

Note: Pipeline is correct as of April 2016. Phase 1 includes also projects designated for IND filing.
* US trade name: CINQAIR®